This is an exciting time to be working in medical innovation. Science is driving new avenues of research and development often spanning different sectors within the life science community, and it is clear that future breakthroughs in medical science will involve cross-sectoral discoveries.
With the pharmaceutical, medical technology, biotechnology, digital health and vaccine industries on board as partners alongside the European Union, IHI is well placed to forge successful, cross-sectoral, collaborative projects. We are confident that this approach will advance the competitiveness of Europe’s life sciences sector and contribute to EU policies in the fields of health and innovation. Most importantly, by working closely with patients, universities and the wider healthcare community, our projects will deliver meaningful results that will have a real impact in areas of unmet need.
‘Launching a new public-private partnership is a huge endeavour and we will work hard in the coming months to set up our new governance structures and launch our first Call for proposals as rapidly as possible,’ said IHI Executive Director Dr Pierre Meulien. ‘We look forward to working with the European Commission, COCIR, EFPIA (including Vaccines Europe), EuropaBio and MedTech Europe on making IHI a success.’
Meanwhile we are immensely proud of what we have achieved as the Innovative Medicines Initiative (IMI). We will continue to manage the remaining IMI projects and actively promote their successes through our IHI communication channels in the years to come.
On a practical note, in the coming weeks, we will be moving our communication channels from IMI to IHI. This will take some time and we will continue to add content to IHI channels as and when we get things up and running. Please bear with us while this happens! In the meantime, if you have any questions about IHI or IMI, don’t hesitate to contact us. Our e-mail addresses will change, but you will still be able to contact us via our @imi.europa.eu addresses for a while yet.